Objetivo Battling human neurodegenerative pathologies, and their pervasive societal impact, is a global multi-billion Euro enterprise. Ageing is universally associated with marked decrease of neuronal function and higher susceptibility to neurodegeneration. In human populations, this is manifested as an ever-increasing prevalence of devastating neurodegenerative conditions, including Alzheimer’s and Parkinson’s disease, stroke, several ataxias, and other types of dementia. Development of therapeutic interventions against such maladies is becoming a pressing priority. Drug discovery and drug target identification are two intimately linked facets of intervention strategies aimed at effectively combating human disorders. Genes linked to human diseases often function in evolutionary conserved pathways, readily dissected in simple model organisms. Such organisms provide attractive platforms for devising and streamlining efficient drug discovery and target identification methodologies. During the course of the ERC project NeuronAge, we developed a convenient and versatile platform for high-throughput chemical compound screening based on the nematode C. elegans (Nature 521: 525; Nature 490: 213). This innovative platform uniquely combines state-of-the-art microfluidics technologies for imaging and manipulation of neurons in vivo, with the experimental prowess of C. elegans, a highly malleable genetic model, which offers a precisely defined nervous system, two features that are not available in any other organism. We propose to: (1) bring this high-throughput compound screening system to pre-demonstration stage; (2) evaluate its dependability for drug target identification and drug discovery; (3) file US and European patent applications for IPR protection; and (4) identify potential commercialization opportunities. The overarching aim is to facilitate the exploitation of the innovation generated in the context of NeuronAge towards the betterment of human health and quality of life. Ámbito científico medical and health sciencesbasic medicinepharmacology and pharmacydrug discoverymedical and health sciencesbasic medicineneurologydementiaalzheimermedical and health sciencesbasic medicinepathologymedical and health sciencesbasic medicineneurologystrokemedical and health sciencesbasic medicineneurologyparkinson Programa(s) H2020-EU.1.1. - EXCELLENT SCIENCE - European Research Council (ERC) Main Programme Tema(s) ERC-PoC-2016 - ERC-Proof of Concept-2016 Convocatoria de propuestas ERC-2016-PoC Consulte otros proyectos de esta convocatoria Régimen de financiación ERC-POC - Proof of Concept Grant Institución de acogida IDRYMA TECHNOLOGIAS KAI EREVNAS Aportación neta de la UEn € 150 000,00 Dirección N PLASTIRA STR 100 70013 Irakleio Grecia Ver en el mapa Región Νησιά Αιγαίου Κρήτη Ηράκλειο Tipo de actividad Research Organisations Enlaces Contactar con la organización Opens in new window Sitio web Opens in new window Participación en los programas de I+D de la UE Opens in new window Red de colaboración de HORIZON Opens in new window Coste total € 150 000,00 Beneficiarios (1) Ordenar alfabéticamente Ordenar por aportación neta de la UE Ampliar todo Contraer todo IDRYMA TECHNOLOGIAS KAI EREVNAS Grecia Aportación neta de la UEn € 150 000,00 Dirección N PLASTIRA STR 100 70013 Irakleio Ver en el mapa Región Νησιά Αιγαίου Κρήτη Ηράκλειο Tipo de actividad Research Organisations Enlaces Contactar con la organización Opens in new window Sitio web Opens in new window Participación en los programas de I+D de la UE Opens in new window Red de colaboración de HORIZON Opens in new window Coste total € 150 000,00